Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Nancy Holekamp, Steven B. Duff, Yamina Rajput & Vincent Garmo. (2020) Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data. Journal of Medical Economics 23:3, pages 287-296.
Read now
Read now
Rhiannon Kamstra, Mike Durkin, Jennifer Cai, Brahim Bookhart, Marie-Hélène Lafeuille, Dominic Pilon, Sean Tiggelaar, Ameur M. Manceur & Patrick Lefebvre. (2019) Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials. Journal of Medical Economics 22:3, pages 280-287.
Read now
Read now
Kathleen A Fairman, Lindsay E Davis & David A Sclar. (2017) Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice. Therapeutics and Clinical Risk Management 13, pages 957-965.
Read now
Read now
Wenjie Zhang, Yi Han, John G. Fort, David Schofield & James P. Tursi. (2017) The budget impact of using enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg to prevent recurrent cardiovascular events. Journal of Medical Economics 20:6, pages 592-598.
Read now
Read now
Peter P. Toth, Mark Danese, Guillermo Villa, Yi Qian, Anne Beaubrun, Armando Lira & Jeroen P. Jansen. (2017) Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. Journal of Medical Economics 20:6, pages 555-564.
Read now
Read now
Articles from other publishers (9)
Alejandro Arrieta, John Woods, Gregory Wozniak, Stavros Tsipas, Michael Rakotz & Stephen Jay. (2021) Return on investment of self-measured blood pressure is associated with its use in preventing false diagnoses, not monitoring hypertension. PLOS ONE 16:6, pages e0252701.
Crossref
Crossref
Brystana G. Kaufman, Bradi B. Granger, Jie-Lena Sun, Gillian Sanders, Donald H. TaylorJrJr, Daniel B. Mark, Haider Warraich, Mona Fiuzat, Karen Steinhauser, James A. Tulsky, Joseph G. Rogers, Christopher O'Connor & Robert J. Mentz. (2021) The Cost-Effectiveness of Palliative Care: Insights from the PAL-HF Trial. Journal of Cardiac Failure 27:6, pages 662-669.
Crossref
Crossref
Ivy Dong & Elizabeth Klodas. (2020) Healthcare Cost Implications of Utilizing a Dietary Intervention to Lower LDL Cholesterol: Proof of Concept Actuarial Analysis and Recommendations. Current Cardiology Reports 22:11.
Crossref
Crossref
Güvenç Koçkaya, Gülpembe Ergin Oğuzhan, Bülent Özin, Kerem Can Yılmaz, Orçun Çiftçi, Filiz Çavuş, Amir Mustapha Sharaf, Nazım Buyuktuna, Tansu Buyukısık & Mete Saylan. (2019) Cost analysis of management of cardiovascular disease comorbidities in Turkey. Journal of Pharmaceutical Health Services Research 10:2, pages 197-202.
Crossref
Crossref
Pooyan KazemianDeborah J. WexlerNaomi F. FieldsRobert A. ParkerAmy ZhengRochelle P. Walensky. (2019) Development and Validation of PREDICT-DM: A New Microsimulation Model to Project and Evaluate Complications and Treatments of Type 2 Diabetes Mellitus. Diabetes Technology & Therapeutics 21:6, pages 344-355.
Crossref
Crossref
Joshua D. Brown, Rich Sheer, Margaret Pasquale, Lavanya Sudharshan, Kirsten Axelsen, Prasun Subedi, Daniel Wiederkehr, Fred Brownfield & Sachin Kamal-Bahl. (2018) Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States. Value in Health 21:1, pages 33-40.
Crossref
Crossref
Thomas A. Pearson. (2017) Understanding the Impact of Hyperlipidemia Treatment on Medical Expenditures for Cardiovascular Disease. Medical Care 55:1, pages 1-3.
Crossref
Crossref
Shravanthi R. Gandra, Guillermo Villa, Gregg C. Fonarow, Mickael Lothgren, Peter Lindgren, Ransi Somaratne & Ben van Hout. (2016)
Cost‐Effectiveness of
LDL
‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
. Clinical Cardiology 39:6, pages 313-320.
Crossref
Crossref
. (2015) Cardiovascular events costly in high-risk patients. PharmacoEconomics & Outcomes News 730:1, pages 9-9.
Crossref
Crossref